临床试验/IRCT20220211053992N39

IRCT20220211053992N39招募中Unknown

In vivo fasted-state bioequivalence study of Fexofenadine 120 mg tablet manufactured by Exir Pharmaceutical Co. compared to innovator product

Tabriz University of Medical Sciences0 个研究点目标入组 24 人开始时间: 待定最近更新: 2024年8月26日

适应症

试验速览

阶段: Unknown
状态: 招募中
发起方: Tabriz University of Medical Sciences
入组人数: 24

研究概览入排标准研究者记录与标识符相似试验

研究概览

简要总结

暂无简介。

研究设计

研究类型: Interventional

入排标准

年龄范围: 18 years 至 55 years（—）
性别: All

入选标准

•General Health (in terms of Liver, Heart and Kidney diseases)
•Age between 18 to 55 years

排除标准

•History of cardiovascular, liver, and kidney disease
•Alcohol and drug addiction
•History of drug allergy

研究者

发起方

Tabriz University of Medical Sciences

相似试验

Investigating the in vivo bioequivalence of Fexofenadine suspensioIn the present study, the products will be administered to healthy volunteers..

IRCT20210519051345N24Tabriz University of Medical Sciences24

Investigating the in vivo bioequivalence of Fluoxetine capsuleIn the present study, the products will be administered to healthy volunteers..

IRCT20210519051345N26Tabriz University of Medical Sciences24

In vivo Bioequivalence study of Famotidine tablet

IRCT20220211053992N35Tabriz University of Medical Sciences24

Bioequivalence study of Famotidine 40 mg tablet.

IRCT20210519051345N39Tabriz University of Medical Sciences24

In vivo Bioequivalence study of Metformin tablet

IRCT20220211053992N26Tabriz University of Medical Sciences24

In vivo Bioequivalence study of Fexofenadine tablet | 临床试验